The S&P 500 could soon hit a new high – and keep on going from there, according to company analysts who see the benchmark gaining 7% over the next year. Which stocks do company analysts see leading the S&P’s march higher (including a biopharmaceutical stock that could double over the next 12 months) – and which stocks might be poised to suffer the biggest losses over the same period? CLICK HERE.